Archived weekly brief

Weekly NADAC Price Changes

A weekly executive brief covering the pricing movements that matter most to market strategy and reimbursement planning.

Week of November 11, 2026

Compared with November 4, 2026

Weekly NADAC pricing brief
Published NDCs
30,157
Price increases
0
Price decreases
0
Unchanged prices
30,096

NADAC weekly update: no price changes among comparable NDCs — 2026-11-11

The CMS publication dated 2026-11-11 contains 30,157 priced NDCs in our data. Of the 30,096 NDCs also priced in the 2026-11-04 publication, 0 changed and 30,096 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.

Key takeaways

  • 0 NDCs increased and 0 decreased compared with the 2026-11-04 publication.
  • 30,096 comparable NDCs retained the same published price.
  • 61 NDCs have no matching price in the 2026-11-04 publication and are excluded from change calculations.

What to watch

Review affected NDCs

Check the exact NDC and pricing unit against your purchasing records before applying an update.

Next publication

The next ingested CMS publication will receive its own edition, even if comparable prices remain unchanged.

Weekly price movement

No comparable price changes were found in this publication. NDCs without a matching previous price are excluded from the comparison.

Notes and methodology

How the weekly brief calculations were ranked, aggregated, and preserved for archive consistency.

Publication comparison

Prices are compared between the two CMS publication dates shown above, using weekly history snapshots. An unchanged effective date does not mean a publication is missing. NDCs absent from the previous publication are excluded from change calculations; missing prices are not counted as unchanged.

Top mover ranking

There are no comparable price changes to rank in this publication. This edition is still archived under its publication date.

Segment summaries

Drug markets, manufacturers, and therapeutic classes aggregate the same NDC-level deltas. Average move is the mean percent change, while impact is the summed dollar-weighted effect using dispensing-volume exposure when the volume table is available.

Headline cards and archive stability

In editions with headline cards, most pressured class selects the largest positive class impact, and largest manufacturer swing selects the manufacturer with the largest aggregate absolute impact. Every weekly brief stores a frozen snapshot so archived pages do not drift when live NADAC data changes.

More archived editions

Each edition is permanently archived under its release date.

Full archive

Week of November 4, 2026

NADAC weekly update: no price changes among comparable NDCs — 2026-11-04

The CMS publication dated 2026-11-04 contains 30,102 priced NDCs in our data. Of the 30,102 NDCs also priced in the 2026-10-28 publication, 0 changed and 30,102 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.

Week of October 28, 2026

NADAC weekly update: 3 NDCs changed — 2026-10-28

The CMS publication dated 2026-10-28 contains 30,167 priced NDCs in our data. Of the 30,094 NDCs also priced in the 2026-10-21 publication, 3 changed and 30,091 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.

Week of October 21, 2026

NADAC Week of Oct 21: Balanced Price Movement Masks Concentrated Spikes in Biologics and Glucagon

The October 21, 2026 NADAC release covered 30,095 NDCs, with 29,992 eligible for week-over-week comparison. Of these, 28,712 (95.7%) changed price, split nearly evenly between 14,883 increases and 13,829 decreases, alongside 1,280 unchanged NDCs and 103 without a prior comparison. This near-even split signals broad repricing activity rather than a directional market-wide trend. The largest single dollar movements were concentrated in a handful of specialty products: a $1.8M increase tied to a single Ofatumumab (Kesimpta) NDC and a $853.2K decline led by Glucagon products, particularly the Amphastar emergency kit (-12.8%). Manufacturer-level activity shows Novartis and AbbVie posting the largest aggregate upward swings ($1.9M and $1.2M respectively) across dozens of products, while Amphastar and Prasco Laboratories saw net declines. Therapeutic class data shows the top class by dollar impact, CD20-directed Cytolytic Antibody, reflects just one drug, underscoring that headline-level 'most pressured class' figures can be driven by a single product rather than category-wide pressure. In contrast, broader classes like alpha-Adrenergic Agonist (252 drugs) and Progestin (125 drugs) show more distributed movement, better reflecting true market breadth this week.

Explore the broader trend ecosystem